Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

U.S. stock futures rose on Monday after Friday’s sharp fall as investors digested the tariff updates and earnings reports.

The task ahead of Vertex now is to migrate patients already ... (liraglutide), used to treat type 2 diabetes, from India's Hikma Pharma. Victoza has been largely superseded by Novo Nordisk's ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion ...

Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.

Vertex Pharmaceuticals Incorporated VRTX will release its fourth-quarter financial results, after the closing bell, on Monday, Feb. 10, 2025. Analysts expect the Boston, Massachusetts-based ...